We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+56.43%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$172M
AUM Growth
–
Cap. Flow
+$143M
Cap. Flow
% of AUM
83.1%
Top 10 Holdings %
Top 10 Hldgs %
34.38%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$6.7M |
| 2 |
Insmed
INSM
|
+$6.39M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.26M |
| 4 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$5.25M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$5.01M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.76% |
| 2 | Miscellaneous | 4.88% |
| 3 | Financials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vericel Corp
VCEL
$2.1B
| $8.69M | 5.05% |
+281,346
| New | +$6.7M |
|
2
CALL
Biogen
BIIB
$32.3B
| $7.35M | 4.27% |
+30,000
| New | +$7.74M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.36M | 3.7% |
+200,000
| New | +$5.26M |
|
4
Delcath Systems
DCTH
$567M
| $6.3M | 3.66% |
+351,616
| New | +$4.82M |
|
|
5
Insmed
INSM
$25.9B
| $5.83M | 3.38% |
+175,000
| New | +$6.39M |
|
|
AMYT
6
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $5.7M | 3.31% |
+402,556
| New | +$5.25M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.01M | 2.91% |
+227,388
| New | +$5.01M |
|
8
Arvinas
ARVN
$600M
| $4.67M | 2.71% |
+55,000
| New | +$1.9M |
|
9
Larimar Therapeutics
LRMR
$417M
| $4.65M | 2.7% |
+217,203
| New | +$4.35M |
|
10
Immunovant
IMVT
$8.51B
| $4.62M | 2.68% |
+100,000
| New | +$4.62M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.39M | 2.55% |
+20,000
| New | +$4.32M |
|
12
Curis
CRIS
$3.61M
| $4.34M | 2.52% |
+1,325
| New | +$1.59M |
|
13
Halozyme
HALO
$12B
| $4.27M | 2.48% |
+100,000
| New | +$3.59M |
|
|
TCRR
14
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $4.21M | 2.44% |
+136,000
| New | +$3.44M |
|
15
Sutro Biopharma
STRO
$339M
| $4.02M | 2.33% |
+18,500
| New | +$3.06M |
|
|
IMGN
16
DELISTED
Immunogen Inc
IMGN
| $3.87M | 2.25% |
+600,000
| New | +$3.5M |
|
|
EPIX
17
DELISTED
ESSA Pharma
EPIX
| $3.85M | 2.24% |
+322,917
| New | +$2.27M |
|
18
Cellectar Biosciences
CLRB
$23.9M
| $3.69M | 2.14% |
+5,909
| New | +$2.72M |
|
|
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
| $3.33M | 1.93% |
+53,766
| New | +$3.08M |
|
20
Kura Oncology
KURA
$1.13B
| $2.94M | 1.71% |
+90,000
| New | +$3.16M |
|
21
Ascendis Pharma A/S
ASND
$16.3B
| $2.93M | 1.7% |
+17,556
| New | +$2.9M |
|
|
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.85M | 1.65% |
+406,665
| New | +$3.17M |
|
23
Evogene
EVGN
$8.68M
| $2.82M | 1.64% |
+60,000
| New | +$2.12M |
|
24
Cogent Biosciences
COGT
$6.02B
| $2.64M | 1.53% |
+235,066
| New | +$2.58M |
|
25
MoonLake Immunotherapeutics
MLTX
$1.28B
| $2.44M | 1.42% |
+215,071
| New | +$2.28M |
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Silverarc Capital Management, which disclosed 84 positions worth $172M. Its ten largest holdings account for 34% of the portfolio.
Its largest position is Vericel Corp: 281,346 shares worth $8.69M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous and Financials.
- Silverarc Capital Management's largest Q4 2020 buy was Vericel Corp: 281,346 shares worth $8.69M.
- Silverarc Capital Management's ten largest holdings make up 34% of its $172M portfolio in Q4 2020.
- Silverarc Capital Management disclosed 84 positions in Q4 2020, its first 13F filing on record.
Based on Silverarc Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.